ArriVent BioPharma, Inc. Common Stock (AVBP) — Financial Flexibility Index
ArriVent BioPharma, Inc. Common Stock (AVBP) has a Financial Flexibility Index of -1.65x as of March 2026. Free cash flow of $-41.89 Million (operating CF $-41.89 Million minus capex $0.00) represents -2% of total liabilities ($25.32 Million). Check AVBP strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
ArriVent BioPharma, Inc. Common Stock Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for ArriVent BioPharma, Inc. Common Stock across 5 annual periods. See ArriVent BioPharma, Inc. Common Stock short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for ArriVent BioPharma, Inc. Common Stock (2021–2025)
Year-by-year free cash flow to debt coverage for ArriVent BioPharma, Inc. Common Stock. For the full company profile including market capitalisation, see AVBP market cap.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -6.19x | $-160.59 Million | $-160.59 Million | $25.95 Million | ▼ -52.4% |
| 2024 | -4.06x | $-70.21 Million | $-70.21 Million | $17.29 Million | ▲ +14.2% |
| 2023 | -4.73x | $-55.84 Million | $-55.84 Million | $11.80 Million | ▲ +9.2% |
| 2022 | -5.21x | $-43.63 Million | $-43.63 Million | $8.37 Million | ▲ +24.7% |
| 2021 | -6.92x | $-12.59 Million | $-12.59 Million | $1.82 Million | — |